581 related articles for article (PubMed ID: 30027399)
21. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
[TBL] [Abstract][Full Text] [Related]
22. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
23. Continuous dopamine-receptor stimulation in early Parkinson's disease.
Olanow W; Schapira AH; Rascol O
Trends Neurosci; 2000 Oct; 23(10 Suppl):S117-26. PubMed ID: 11052229
[TBL] [Abstract][Full Text] [Related]
24. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.
Yoo HS; Chung SJ; Chung SJ; Moon H; Oh JS; Kim JS; Hong JY; Ye BS; Sohn YH; Lee PH
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):423-431. PubMed ID: 29075830
[TBL] [Abstract][Full Text] [Related]
25. The impact of early versus late levodopa administration.
Yahalom G; Cohen OS; Warmann-Alaluf N; Shabat C; Strauss H; Elincx-Benizri S; Israeli-Korn S; Stein E; Greenbaum L; Hassin-Baer S
J Neural Transm (Vienna); 2017 Apr; 124(4):471-476. PubMed ID: 28004202
[TBL] [Abstract][Full Text] [Related]
26. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
Horstink MW; Zijlmans JC; Pasman JW; Berger HJ; van't Hof MA
J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):224-6. PubMed ID: 2324754
[TBL] [Abstract][Full Text] [Related]
27. A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients.
Simon N; Viallet F; Boulamery A; Eusebio A; Gayraud D; Azulay JP
Eur J Clin Pharmacol; 2016 Apr; 72(4):423-30. PubMed ID: 26936272
[TBL] [Abstract][Full Text] [Related]
28. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
[TBL] [Abstract][Full Text] [Related]
29. Optimising levodopa therapy for the management of Parkinson's disease.
Stocchi F
J Neurol; 2005 Oct; 252 Suppl 4():IV43-IV48. PubMed ID: 16222437
[TBL] [Abstract][Full Text] [Related]
30. Age of Parkinson's disease onset as a predictor for the development of dyskinesia.
Ku S; Glass GA
Mov Disord; 2010 Jul; 25(9):1177-82. PubMed ID: 20310028
[TBL] [Abstract][Full Text] [Related]
31. [Management of Parkinson's disease in 2009].
Maertens de Noordhout A
Rev Med Suisse; 2009 Aug; 5(214):1650-5. PubMed ID: 19772196
[TBL] [Abstract][Full Text] [Related]
32. Levodopa and the progression of Parkinson's disease.
Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
[TBL] [Abstract][Full Text] [Related]
33. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
[TBL] [Abstract][Full Text] [Related]
34. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
Watts RL; Lyons KE; Pahwa R; Sethi K; Stern M; Hauser RA; Olanow W; Gray AM; Adams B; Earl NL;
Mov Disord; 2010 May; 25(7):858-66. PubMed ID: 20461803
[TBL] [Abstract][Full Text] [Related]
35. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight.
Sharma JC; Ross IN; Rascol O; Brooks D
Eur J Neurol; 2008 May; 15(5):493-6. PubMed ID: 18355302
[TBL] [Abstract][Full Text] [Related]
36. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA
Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
[TBL] [Abstract][Full Text] [Related]
37. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
[TBL] [Abstract][Full Text] [Related]
38. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease.
Jenner P
Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S3-7. PubMed ID: 15180131
[TBL] [Abstract][Full Text] [Related]
39. Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.
Mizuno Y; Shimoda S; Origasa H
J Neural Transm (Vienna); 2018 Jan; 125(1):35-43. PubMed ID: 28091751
[TBL] [Abstract][Full Text] [Related]
40. Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
Bjornestad A; Forsaa EB; Pedersen KF; Tysnes OB; Larsen JP; Alves G
Parkinsonism Relat Disord; 2016 Jan; 22():48-53. PubMed ID: 26585090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
